


Please type a plus sign (+) inside this box → [+]



PTO/SB08A/B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are to respond to a collection of information unless it contains a valid OMB control number

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

SHEET 1 of 1

COMPLETE IF KNOWN

Application Number	10/689,022
Confirmation Number	
Filing Date	10/20/2003
First Named Inventor	Frank Hallock Ebetino
Group Art Unit	
Examiner Name	
Attorney Docket Number	9071M


U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
LB	1	US-5,783,582	07/21/1998	Guo et al.	
	2	US-5,804,578	09/08/1998	Chakravarty et al.	
	3	US-5,721,250	02/24/1998	Morriello et al.	
	4	US-5,494,919	02/27/1996	Morriello et al.	
	5	US-5,721,251	02/24/1998	Chen et al.	
	6	US-5,880,125	03/09/1999	Nargund	
	7	US-5,965,565	10/12/1999	Chen et al.	
	8	US-5,536,716	07/16/1996	Chen et al.	
	9	US-6,350,760 B1	02/26/2002	Bakshi et al.	
	10	US-5,492,916	02/20/1996	Morriello et al.	
	11	US-5,877,182	03/02/1999	Nargund et al.	
	12	US-5,936,089	08/10/1999	Carpino et al.	
	13	US-6,294,534 B1	09/25/2001	Nargund et al.	

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENT								
EXAMINER INITIALS*	Cite No. ¹	Country Code ³ Number ⁴	Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T*	
LB	14	WO 01/70337 A1		09/27/2001	Palucki et al.			
	15	WO 96/13265 A1		05/09/1996	Nargund et al.			
	16	WO 96/02530 A1		02/01/1996	Guo et al.			
	17	WO 94/19367 A1		09/01/1994	Chen et al.			
	18	WO 03/031410 A1		04/17/2003	Neurocrine Biosciences, Inc.			
	19	WO 94/13696 A1		06/23/1994	Chen et al.			
	20	WO 99/64002 A1		12/16/1999	Nargund et al.			
	21	WO 98/10653 A1		03/19/1998	Nargund et al.			
	22	WO 02/00654 A1		01/03/2002	Carpino et al.			
	23	WO 01/91752 A1		12/06/2001	Bakshi et al.			
	24	WO 99/58501 A1		11/18/1999	Hansen et al.			
	25	WO 96/38471 A1		12/05/1996	Carpino et al.			
	26	WO 02/059107 A1		08/01/2002	Backer et al.			
	27	WO 02/15909 A1		02/28/2002	Bakshi			
	28	WO 02/068388 A2		09/06/2002	Ujjainwalla et al.			
	29	WO 02/068387 A2		09/06/2002	Goulet et al.			
	30	WO 00/74679 A1		12/14/2000	Bakshi et al.			
	31	WO 99/55679 A1		11/04/1999	Basu et al.			
	32	WO 02/059117 A1		08/01/2002	Briner et al.			
	33	WO 02/070511 A1		09/12/2002	Yu et al.			
	34	WO 01/70708 A1		09/27/2001	Palucki et al.			
	35	WO 03/031410 A1		04/17/2003	Neurocrine Biosciences, Inc.			
	EXAMINER	F. Benlouch				DATE CONSIDERED	3/3/06	

→ Duplicate of Cite No. 18



Please type a plus sign (+) inside this box → [+]

PTO/SB08A/B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number
Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 1

COMPLETE IF KNOWN

Application Number	10/689,022
Confirmation Number	
Filing Date	October 20, 2003
First Named Inventor	Fmk Hallock Ebetino
Group Art Unit	
Examiner Name	
Attorney Docket Number	9071M

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
EB	1	WO 03/013571 A1	02/20/2003	Palatin Technologies Inc.		
EXAMINER	L. Benhaddou		DATE CONSIDERED 3/3/06			


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08

(Revised for P&G use 10/8/2003)



Please type a plus sign (+) inside this box -> [+]

OCT 25 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

PTO/SB08A (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 3

COMPLETE IF KNOWN

Application Number	10/689,022
Confirmation Number	4104
Filing Date	10/20/2003
First Named Inventor	Frank Hallock Ebetino et al.
Group Art Unit	1646
Examiner Name	
Attorney Docket Number	9071M

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
EB	1	US-4,251,438	02/17/1981	Moon	
		US-			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
EB	2	WO 02/076947 A1	10/03/2002	Schering Corp.		
	3	WO 02/48124 A2	06/20/2002	F. Hoffmann-La Roche AG; Vernalis Research Limited		
	4	WO 02/059108 A1	08/01/2002	Eli Lilly and Co.		
	5	WO 02/059095 A1	08/01/2002	Eli Lilly and Co.		
	6	WO 01/05331 A1	01/25/2001	Biocompatibles Ltd.		
	7	WO 00/66558 A1	11/09/2000	Schering Corp.		
	8	WO 02/079194 A1	10/10/2002	Schering Corp.		
	9	WO 98/52929 A1	11/26/1998	Pfizer Inc.		
	10	WO 02/064576 A1	08/22/2002	CV Therapeutics Inc.		
	11	WO 98/05292 A2	02/12/1998	Schering Corp.		
	12	WO 96/31478 A1	10/10/1996	Schering Corp.		
	13	WO 03/009850 A1	02/06/2003	Amgen Inc.		
	14	WO 02/085925 A2	10/31/2002	Procter & Gamble Co.		
	15	WO 03/061660 A1	07/31/2003	Eli Lilly and Co.		
EXAMINER	<i>E Bernhardt</i>		DATE CONSIDERED 3/2/06			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08

(Revised for P&G use 10/8/2003)

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p> <p>SHEET 2 of 3</p>	COMPLETE IF KNOWN	
	Application Number	10/689,022
	Confirmation Number	4104
	Filing Date	10/20/2003
	First Named Inventor	Frank Hallock Ebetino et al.
	Group Art Unit	1646
	Examiner Name	
Attorney Docket Number	9071M	

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	US-			
		US-			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
EB	16	WO 03/022835 A1	03/20/2003	Schering Corp.		
EB	17	WO 03/035627 A1	05/01/2003	Pfizer Products Inc.		
EB	18	EP 1 122242 A1	08/08/2001	Yamanouchi Pharmaceutical Co. Ltd.		
EXAMINER <i>J Benhuck</i>			DATE CONSIDERED <i>3/2/04</i>			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08

(Revised for P&G use 10/8/2003)

Please type a plus sign (+) inside this box → [+]

PTO/SB08B (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) SHEET 3 of 3	COMPLETE IF KNOWN	
	Application Number	10/689,022
	Confirmation Number	4104
	Filing Date	10/20/2003
	First Named Inventor	Frank Hallock Ebetino et al.
	Group Art Unit	1646
	Examiner Name	
Attorney Docket Number	9071M	

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
FB	19 ✓	ANONYMOUS, "Mechanism(s) of Formation of Acrylamide in Food: Background", INTERNET ARTICLE, (retrieved from the Internet: URL: http://www.jitsan.umd.edu/Acrylamide/WG1/WG1_Mech_BG_Paper.pdf on 04-03-2003); XP002237515, pp 1-23.	
	20 ✓	MOTTRAM, D.S. et al., "Acrylamide is formed in the Maillard reaction", <i>Nature</i> , 2002, pp. 448-449, Vol. 419.	
	21 ✓	STADLER, R.H. et al., "Acrylamide from Maillard reaction products," <i>Nature</i> , 2002, pp. 449-450, Vol. 419.	
	22 ✓	YAYLAYAN, V.A. et al., "Why asparagine needs carbohydrates to generate acrylamide", <i>J. of Agric. Food Chem.</i> , 2003, pp. 1753-1757, Vol. 51.	
	23 ✓	JACKSON, L., "Formation Of Acrylamide In Food", <i>Food Advisory committee. Contaminants and Natural Toxicants Subcommittee Meeting</i> , December 4-5, 2002, pp. 10-1.	
	24 ✓	ZYZAK, D.V. et al., "Acrylamide formation mechanism in heated food", <i>J. Agric. Food Chem.</i> , 2003, pp. 4782-4787, Vol. 51, No. 16.	
	25 ✓	FRIEDMAN, M., "Chemistry, Biochemistry and Safety of Acrylamide. A Review", <i>J. Agric. Food Chem.</i> , 2003, pp. 4504-4526, Vol. 51, No. 16.	
	26 ✓	ELMORE, J.S. et al., "Compilation of free amino acids data for various food raw materials, showing the relative contributions of asparagine, glutamine, aspartic acid and glutamic acid to the free amino acid composition", INTERNET ARTICLE, (retrieved from the Internet: URL: http://www.jitsan.umd.edu/presentations/acrylamide2002/wgl_asparagine_in_foods.pdf on 04-08-20034); XP002276621.	
	27 ✓	MOTTRAM D. et al., "Suggested Mechanism for the formation of acrylamide in foods", INTERNET ARTICLE, (retrieved from the Internet: URL: http://www.jitsan.umd.edu/presentations/acrylamide2002/wgl_Mottram_D.pdf on 04-08-20034); XP002276622.	
	28 ✓	FALBE, J. et al., "Roompp Lexikon Lebensmittelchemie, ASPARAGIN", pp. 76 (XP002268124).	
	29 ✓	YAMASHITA, T. et al., "Synthesis and opiate activity of pseudo-tetrapeptides containing chiral piperazin-2-one and piperazine derivatives", <i>Chem. & Pharm. Bulletin</i> , 1997, pp. 1940-1944, Vol. 45, No. 12.	
30 ✓	MOON, M.W. et al., "Piperazinone Enkephalin analogs", <i>Pept. Synth., Struct., Funct., Proc. Am. Pept. Symp.</i> , 7 th , 1981, pp. 641-644, Editor(s): Rich, Daniel H.; Gross, Erhard., Publisher: Pierce Chem. Co., Rockford, ILL.		
31 ✓	GROSZKOWSKI, S. et al., "Synthesis of 1,4-Di(pyrrolidineacyl)piperazines, of 1,1-Di(piperidineacyl)-2-methylpiperazines and their quaternary salts", <i>Roczniki chemii</i> , 1973, pp. 1277-1280, Vol. 47, No. 6.		
EXAMINER		DATE CONSIDERED 3/2/06	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.